Trevi Therapeutics, Inc. (TRVI): Price and Financial Metrics


Trevi Therapeutics, Inc. (TRVI): $2.30

0.07 (+3.14%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

TRVI Stock Price Chart Interactive Chart >

Price chart for TRVI

TRVI Price/Volume Stats

Current price $2.30 52-week high $8.50
Prev. close $2.23 52-week low $1.94
Day low $2.30 Volume 460
Day high $2.30 Avg. volume 76,034
50-day MA $2.26 Dividend yield N/A
200-day MA $2.97 Market Cap 45.83M

Trevi Therapeutics, Inc. (TRVI) Company Bio


Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.


TRVI Latest News Stream


Event/Time News Detail
Loading, please wait...

TRVI Latest Social Stream


Loading social stream, please wait...

View Full TRVI Social Stream

Latest TRVI News From Around the Web

Below are the latest news stories about Trevi Therapeutics Inc that investors may wish to consider to help them evaluate TRVI as an investment opportunity.

Trevi Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference

NEW HAVEN, Conn., April 07, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will participate in a virtual fireside chat, as well as host investor meetings, at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021. Trevi’s presentation is scheduled for 2:15 p.m. ET. A live webcast of the virtual fireside chat can be accessed by visiting ‘News & Events’ in the ‘Investors & News’ section on the Company’s website at www.trevitherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company’s website following the confe...

Yahoo | April 7, 2021

Trevi Therapeutics Earnings : What to expect Stock market Insights & financial analysis

Trevi Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…

Stock Market Daily | March 15, 2021

Trevi Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference

NEW HAVEN, Conn., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will participate in a virtual fireside chat, as well as host virtual investor meetings, at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021. Presentation Time: 4:20 p.m. ET A live webcast of the virtual fireside chat can be accessed by visiting ‘News & Events’ in the ‘Investors & News’ section on the Company’s website at www.trevitherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company’s website following the conference. ...

Yahoo | February 18, 2021

Trevi Therapeutics to Present at Stifel Healthcare Conference

NEW HAVEN, Conn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the…

GlobeNewswire | November 10, 2020

Trevi Therapeutics to Report Q3 2020 Financial Results on November 11

Conference Call and Webcast to be Held at 4:30 p.m. ET

GlobeNewswire | November 4, 2020

Read More 'TRVI' Stories Here

TRVI Price Returns

1-mo 11.65%
3-mo -17.27%
6-mo -21.77%
1-year -49.34%
3-year N/A
5-year N/A
YTD -4.96%
2020 -35.47%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.863 seconds.